查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584133

肝癌药物市场，按药物类别、治疗类型、给药途径、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Liver Cancer Drug Market, By Drug Class, By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年肝癌药物市场规模为31.519亿美元，2024年至2032年复合年增长率为17.82%。

肝癌药物市场-市场动态

肝癌发生率上升推动肝癌药物市场成长

根据世界卫生组织报告，肝癌发病率的上升极大地推动了肝癌药物市场的成长，这表明过去二十年肝癌病例增加了75%以上。这一令人震惊的趋势主要归因于乙型肝炎和丙型肝炎感染率上升、过量饮酒和肥胖，美国癌症协会估计，到 2023 年，仅美国就将诊断出约 43,000 例新肝癌病例。随着人们对早期检测和治疗重要性的认识不断增强，製药公司正在透过开发创新疗法来应对。例如，免疫检查点抑制剂等标靶治疗的最新进展可望提高晚期肝癌患者的存活率。此外，美国肝病研究协会等组织正在推动研究和临床试验，以增强治疗选择并更好地了解这种疾病，从而满足这个快速发展的市场对有效疗法的迫切需求。

肝癌药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 17.82% 左右的复合年增长率成长

根据药物类别细分，预计 VEGF 抑制剂将在 2023 年显示最大的市场份额

从治疗类型细分来看，2023年标靶治疗为主导类型

根据给药途径细分，2023年口服是领先类型

按地区划分，北美是 2023 年的主要收入来源

肝癌药物市场-細項分析：

全球肝癌药物市场根据药物类别、治疗类型、给药途径、最终用户和地区进行细分。

根据药物类别，市场分为四类：VEGF抑制剂、PD-1/PD-L1抑制剂、酪胺酸激酶抑制剂和免疫检查点抑制剂。 VEGF 抑制剂因其在治疗肝细胞癌方面的既定功效而在肝癌药物市场中排名最高。 PD-1/PD-L1 抑制剂紧随其后，提供了有前景的免疫疗法选择。接下来是酪胺酸激酶抑制剂 (TKI)，而免疫检查点抑制剂在晚期病例中越来越受欢迎。

根据治疗类型，市场分为四类：化疗、标靶治疗、免疫治疗和合併治疗。标靶治疗因其治疗的有效性和精确性而引领肝癌药物市场。免疫疗法紧随其后，为晚期肝癌提供创新选择。联合疗法则位居第二，而化疗仍是一种传统方法，在晚期阶段疗效有限。

肝癌药物市场 - 地理洞察

在先进的医疗基础设施和肝癌高盛行率的推动下，北美在肝癌药物市场上占据主导地位，尤其是在美国。 2022年，美国食品药物管理局（FDA）批准了乐伐替尼和派姆单抗的新联合疗法，标誌着晚期肝细胞癌（HCC）患者的治疗选择取得了重大进展。此外，美国癌症协会报告称，肝癌发病率一直在稳步上升，促使更多的资金用于旨在更好的诊断工具和治疗方案的研究计划。在欧洲，德国和法国等国家正见证以创新药物组合为重点的临床试验激增，反映出对加强病患照护的承诺。由于肝炎相关肝癌的高盛行率，亚太地区正在成为一个关键地区，在肝癌研究方面投入了大量资金。日本製药公司与研究机构之间的合作等合作旨在加速新疗法的开发，凸显全球有效对抗肝癌的努力。

肝癌药物市场-竞争格局：

肝癌药物市场的竞争格局主要由北美主导，拜耳、百时美施贵宝和默克等主要製药公司都在积极推动其产品组合。 2023年，拜耳宣布推出索拉非尼新配方，旨在提高肝细胞癌（HCC）治疗的患者依从性和结果。同时，百时美施贵宝与国家癌症研究所的合作加速了新型免疫疗法的开发，并显着增强了患者的治疗选择。最近有消息称，默克公司收购了一家专门从事肝癌研究的生物技术公司，巩固了其在市场上的地位，从而扩大了创新疗法的产品线。此外，欧洲市场的活动正在增加，将现有药物与新兴药物结合的联合疗法的临床试验正在进行中，反映出个人化医疗的成长趋势。这些发展凸显了一个动态的竞争环境，在这种环境中，协作、创新和策略伙伴关係对于推动肝癌领域的治疗方案和改善患者的治疗结果至关重要。

最新进展：

2024年8月，百时美施贵宝用于第一线治疗不可切除肝细胞癌的补充生物製剂许可申请被FDA接受。这标誌着在推进此类肝癌患者的治疗选择方面迈出了重要一步。

2024 年 2 月，FDA 授予 BST02 快速通道资格，这是一种治疗所有肝癌类型（包括肝细胞癌和胆管​​癌）的 T 细胞疗法。这种创新疗法利用肿瘤浸润淋巴细胞，并准备在 1/2 期临床试验中进行评估。

目录

第一章：肝癌药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的肝癌药物市场片段
    • 按治疗类型分類的肝癌药物市场片段
    • 依给药途径分類的肝癌药物市场片段
    • 最终用户的肝癌药物市场片段
    • 按国家/地区分類的肝癌药物市场片段
    • 按地区分類的肝癌药物市场片段
  • 竞争洞察

第 3 章：肝癌药物主要市场趋势

  • 肝癌药物市场驱动因素
    • 市场驱动因素的影响分析
  • 肝癌药物市场限制
    • 市场限制影响分析
  • 肝癌药物市场机会
  • 肝癌药物市场未来趋势

第 4 章：肝癌药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：肝癌药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：肝癌药物市场格局

  • 2023 年肝癌药物市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：肝癌药物市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 血管内皮生长因子抑制剂
    • PD-1/PD-L1 抑制剂
    • 酪胺酸激酶抑制剂 (TKI)
    • 免疫检查点抑制剂

第 8 章：肝癌药物市场 - 依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 化疗
    • 标靶治疗
    • 免疫疗法
    • 联合疗法

第 9 章：肝癌药物市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 静脉

第 10 章：肝癌药物市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 肿瘤科诊所
    • 研究所

第 11 章：肝癌药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美肝癌药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按治疗类型）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲肝癌药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按治疗类型）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区肝癌药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（按治疗类型）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲肝癌药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按治疗类型）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲肝癌药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模和预测（按治疗类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析-肝癌药物产业

  • 竞争仪表板
  • 公司简介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Genentech, Inc. (Roche)
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4113

REPORT HIGHLIGHT

Liver Cancer Drug Market size was valued at USD 3,151.90 Million in 2023, expanding at a CAGR of 17.82% from 2024 to 2032.

The Liver Cancer Drug Market focuses on pharmaceutical treatments for hepatocellular carcinoma (HCC), the most common type of liver cancer, accounting for approximately 75% of all liver cancer cases. Rising incidences of liver cancer, attributed to factors like hepatitis infection and alcohol consumption, have heightened the demand for effective therapies. For instance, the World Health Organization estimates that liver cancer caused around 830,000 deaths globally in 2020. The advent of targeted therapies, such as sorafenib and lenvatinib, has transformed treatment protocols, offering new hope for patients. However, challenges persist, including the high cost of innovative treatments and limited access to care in low-resource settings, which can hinder market growth. Furthermore, the lack of early diagnostic tools often results in late-stage diagnosis, complicating treatment options. Nevertheless, opportunities abound in research for novel therapies, particularly immunotherapy and combination treatments, as well as initiatives aimed at increasing awareness and screening, which could lead to earlier diagnosis and better patient outcomes in the liver cancer landscape.

Liver Cancer Drug Market- Market Dynamics

Rising Incidences of Liver Cancer Drive Growth in the Liver Cancer Drug Market

The rising incidences of liver cancer are significantly driving growth in the Liver Cancer Drug Market, as reported by the World Health Organization, which indicates that liver cancer cases have increased by over 75% in the past two decades. This alarming trend is primarily attributed to rising rates of hepatitis B and C infections, excessive alcohol consumption, and obesity, with the American Cancer Society estimating that in 2023, approximately 43,000 new cases of liver cancer will be diagnosed in the U.S. alone. As awareness grows regarding the importance of early detection and treatment, pharmaceutical companies are responding by developing innovative therapies. For instance, recent advancements in targeted therapies, such as immune checkpoint inhibitors, have shown promise in improving survival rates for patients with advanced liver cancer. Additionally, organizations like the American Association for the Study of Liver Diseases are promoting research and clinical trials to enhance treatment options and better understand the disease, thereby addressing the urgent need for effective therapies in this rapidly evolving market.

Liver Cancer Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.82% over the forecast period (2024-2032)

Based on Drug Class segmentation, VEGF Inhibitors were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Targeted Therapy was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Liver Cancer Drug Market- Segmentation Analysis:

The Global Liver Cancer Drug Market is segmented on the basis of Drug Class, Therapy Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: VEGF Inhibitors, PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors, and Immune Checkpoint Inhibitors. VEGF inhibitors rank highest in the Liver Cancer Drug Market due to their established efficacy in treating hepatocellular carcinoma. PD-1/PD-L1 inhibitors follow, offering promising immunotherapeutic options. Tyrosine kinase inhibitors (TKIs) are next, while immune checkpoint inhibitors are gaining traction for advanced cases.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Targeted therapy leads the Liver Cancer Drug Market due to its effectiveness and precision in treatment. Immunotherapy follows closely, providing innovative options for advanced liver cancer. Combination therapy ranks next, while chemotherapy remains a traditional approach with limited efficacy in advanced stages.

Liver Cancer Drug Market- Geographical Insights

North America dominates the Liver Cancer Drug Market, driven by advanced healthcare infrastructure and a high prevalence of liver cancer, particularly in the United States. In 2022, the U.S. Food and Drug Administration (FDA) approved a new combination therapy involving lenvatinib and pembrolizumab, marking a significant advancement in treatment options for patients with advanced hepatocellular carcinoma (HCC). Additionally, the American Cancer Society reported that liver cancer incidence rates have been rising steadily, prompting increased funding for research initiatives aimed at better diagnostic tools and therapeutic options. In Europe, countries like Germany and France are witnessing a surge in clinical trials focusing on innovative drug combinations, reflecting a commitment to enhancing patient care. Asia-Pacific is emerging as a key region, with significant investments in liver cancer research due to the high prevalence of hepatitis-related liver cancer. Collaborations, such as the partnership between pharmaceutical companies and research institutions in Japan, aim to expedite the development of new therapies, highlighting a global effort to combat liver cancer effectively.

Liver Cancer Drug Market- Competitive Landscape:

The competitive landscape of the Liver Cancer Drug Market is predominantly led by North America, where major pharmaceutical companies like Bayer, Bristol-Myers Squibb, and Merck are actively advancing their portfolios. In 2023, Bayer announced the launch of a new formulation of sorafenib, aimed at improving patient adherence and outcomes in hepatocellular carcinoma (HCC) treatment. Meanwhile, Bristol-Myers Squibb's collaboration with the National Cancer Institute has accelerated the development of novel immunotherapies, significantly enhancing treatment options available to patients. In recent news, Merck's acquisition of a biotechnology firm specializing in liver cancer research has fortified its position in the market, allowing for an expanded pipeline of innovative therapies. Additionally, the European market is witnessing increased activity, with clinical trials underway for combination therapies that incorporate existing drugs with emerging agents, reflecting a growing trend towards personalized medicine. These developments highlight a dynamic competitive environment where collaboration, innovation, and strategic partnerships are essential for advancing treatment options and improving patient outcomes in the liver cancer landscape.

Recent Developments:

In August 2024, Bristol Myers Squibb's supplemental biologics license application for the first-line treatment of unresectable hepatocellular carcinoma was accepted by the FDA. This marks a significant step in advancing treatment options for patients with this type of liver cancer.

In February 2024, The FDA granted fast-track designation to BST02, a T-cell therapy for all liver cancer types, including hepatocellular carcinoma and cholangiocarcinoma. This innovative treatment utilizes tumor-infiltrating lymphocytes and is set for evaluation in a phase 1/2 clinical trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LIVER CANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc. (Roche)
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Others

GLOBAL LIVER CANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • VEGF Inhibitors
  • PD-1/PD-L1 Inhibitors
  • Tyrosine Kinase Inhibitors (TKIs)
  • Immune Checkpoint Inhibitors

GLOBAL LIVER CANCER DRUG MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Combination Therapy

GLOBAL LIVER CANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous

GLOBAL LIVER CANCER DRUG MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology Clinics
  • Research Institutes

GLOBAL LIVER CANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Liver Cancer Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Liver Cancer Drug Market Snippet by Drug Class
    • 2.1.2. Liver Cancer Drug Market Snippet by Therapy Type
    • 2.1.3. Liver Cancer Drug Market Snippet by Route of Administration
    • 2.1.4. Liver Cancer Drug Market Snippet by End-User
    • 2.1.5. Liver Cancer Drug Market Snippet by Country
    • 2.1.6. Liver Cancer Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Liver Cancer Drug Key Market Trends

  • 3.1. Liver Cancer Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Liver Cancer Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Liver Cancer Drug Market Opportunities
  • 3.4. Liver Cancer Drug Market Future Trends

4. Liver Cancer Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Liver Cancer Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Liver Cancer Drug Market Landscape

  • 6.1. Liver Cancer Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Liver Cancer Drug Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. VEGF Inhibitors
    • 7.1.3. PD-1/PD-L1 Inhibitors
    • 7.1.4. Tyrosine Kinase Inhibitors (TKIs)
    • 7.1.5. Immune Checkpoint Inhibitors

8. Liver Cancer Drug Market - By Therapy Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Targeted Therapy
    • 8.1.4. Immunotherapy
    • 8.1.5. Combination Therapy

9. Liver Cancer Drug Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous

10. Liver Cancer Drug Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Oncology Clinics
    • 10.1.4. Research Institutes

11. Liver Cancer Drug Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Liver Cancer Drug Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Liver Cancer Drug Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Liver Cancer Drug Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Liver Cancer Drug Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Liver Cancer Drug Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Liver Cancer Drug Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Bristol-Myers Squibb Company
    • 12.2.6. Eisai Co., Ltd.
    • 12.2.7. Eli Lilly and Company
    • 12.2.8. F. Hoffmann-La Roche AG
    • 12.2.9. Genentech, Inc. (Roche)
    • 12.2.10. Gilead Sciences, Inc.
    • 12.2.11. GlaxoSmithKline plc
    • 12.2.12. Merck & Co., Inc.
    • 12.2.13. Novartis AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Sanofi S.A.
    • 12.2.16. Takeda Pharmaceutical Company Limited
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us